Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)	Total	Series D	Series E	Series F	Common Stock Class A and Class B Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Shares, beginning of period (in shares) at Jan. 31, 2019	97,686,390
Balance, beginning of period at Jan. 31, 2019	$ 149,955,000
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Preferred Stock, net of issuance costs (in shares)		15,837,558
Issuance of Preferred Stock, net of issuance costs		$ 51,871,000
Shares, end of period (in shares) at Jan. 31, 2020	113,523,948
Balance, end of period at Jan. 31, 2020	$ 201,826,000
Shares, beginning of period (in shares) at Jan. 31, 2019					31,679,835
Balance, beginning of period at Jan. 31, 2019	(152,594,000)				$ 1,000	$ 3,660,000	$ 177,000	$ (156,432,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)					1,870,974
Issuance of common stock upon exercise of options	899,000					899,000
Vesting of early exercised options	68,000					68,000
Stock based compensation expense	4,359,000					4,359,000
Foreign currency translation adjustments	(378,000)						(378,000)
Net loss	(76,567,000)							(76,567,000)
Shares, end of period (in shares) at Jan. 31, 2020					33,550,809
Balance, end of period at Jan. 31, 2020	$ (224,213,000)				$ 1,000	8,986,000	(201,000)	(232,999,000)
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Preferred Stock, net of issuance costs (in shares)			31,405,183	22,128,982
Issuance of Preferred Stock, net of issuance costs			$ 152,539,000	$ 266,774,000
Shares, end of period (in shares) at Jan. 31, 2021	167,058,113	29,078,931	31,405,183	22,128,982
Balance, end of period at Jan. 31, 2021	$ 621,139,000	$ 95,239,000	$ 152,539,000	$ 266,774,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)					5,358,692
Issuance of common stock upon exercise of options	4,608,000				$ 1,000	4,607,000
Issuance of common stock upon exercise of warrants (in shares)					321,802
Issuance of common stock upon exercise of warrants	200,000					200,000
Issuance of restricted stock for services provided (in shares)					11,013
Issuance of common stock for services provided	47,000					47,000
Vesting of early exercised options	71,000					71,000
Stock based compensation expense	15,958,000					15,958,000
Foreign currency translation adjustments	366,000						366,000
Net loss	(117,573,000)							(117,573,000)
Shares, end of period (in shares) at Jan. 31, 2021					39,242,316
Balance, end of period at Jan. 31, 2021	$ (320,536,000)				$ 2,000	29,869,000	165,000	(350,572,000)
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Preferred Stock, net of issuance costs (in shares)			31,405,183	22,128,982
Conversion of redeemable convertible preferred stock to common stock upon initial public offering (in shares)	(167,058,113)
Conversion of redeemable convertible preferred stock to common stock upon initial public offering	$ (621,139,000)
Shares, end of period (in shares) at Jan. 31, 2022	0
Balance, end of period at Jan. 31, 2022	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of redeemable convertible preferred stock to common stock upon initial public offering (in shares)					169,787,200
Conversion of redeemable convertible preferred stock to common stock upon initial public offering	621,139,000				$ 10,000	621,129,000
Issuance of common stock upon initial public offering and private placement, net of underwriting discounts and commissions (in shares)					41,678,568
Issuance of common stock upon initial public offering and private placements, net of underwriting discounts and commissions	1,380,960,000				$ 4,000	1,380,956,000
Issuance of common stock upon exercise of options (in shares)					9,793,331
Issuance of common stock upon exercise of options	14,621,000				$ 10,000	14,611,000
Issuance of common stock upon exercise of warrants (in shares)					940,953
Issuance of restricted stock for services provided (in shares)					20,000
Issuance of common stock for services provided	500,000					500,000
Vesting of restricted stock units (in shares)					15,218
Issuance of common stock under employee stock purchase plan (in shares)					381,716
Issuance of common stock under employee stock purchase plan	11,356,000					11,356,000
Vesting of early exercised options	572,000					572,000
Issuance of common stock and awards assumed in connection with acquisition (in shares)					7,277,214
Issuance of common stock and awards assumed in connection with Scalyr acquisition	120,320,000				$ 1,000	120,319,000
Issuance of restricted stock awards (in shares)					1,315,099
Stock based compensation expense	92,668,000					92,668,000
Foreign currency translation adjustments	289,000						289,000
Net loss	(271,101,000)
Shares, end of period (in shares) at Jan. 31, 2022					270,451,615
Balance, end of period at Jan. 31, 2022	$ 1,650,788,000				$ 27,000	$ 2,271,980,000	$ 454,000	$ (621,673,000)